Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Adult Grade III Lymphomatoid Granulomatosis
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Contiguous Stage II Adult Burkitt Lymphoma
Contiguous Stage II Adult Diffuse Large Cell Lymphoma
Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma
Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma
Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma
Contiguous Stage II Adult Lymphoblastic Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma
Contiguous Stage II Grade 2 Follicular Lymphoma

Interventions: Drug: R-(-)-gossypol acetic acid
Drug: paclitaxel
Drug: carboplatin
Other: pharmacological study

First Posted Date: 2009-04-30

Last Posted Date: 2013-01-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00891072

Locations: 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Trial Comparing Two Carboplatin Doses in Groups C and D Intraocular Retinoblastoma

Not Applicable

Conditions: Intraocular Retinoblastoma

Interventions: Drug: carboplatin

First Posted Date: 2009-04-28

Last Posted Date: 2012-02-09

Lead Sponsor: All India Institute of Medical Sciences, New Delhi

Target Recruit Count: 60

Registration Number: NCT00889018

Locations: 🇮🇳
Dr RPC AIIMS, Delhi, India

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Sunitinib

First Posted Date: 2009-04-24

Last Posted Date: 2016-09-07

Lead Sponsor: SCRI Development Innovations, LLC

Target Recruit Count: 54

Registration Number: NCT00887575

Locations: 🇺🇸
Holy Cross Hospital, Ft. Lauderdale, Florida, United States
🇺🇸
Florida Cancer Specialists North, Ft. Myers, Florida, United States
🇺🇸
National Capital Clinical Research Consortium, Bethesda, Maryland, United States

and more 11 locations

A Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) (RT0801)

Phase 2

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: carboplatin
Radiation: thoracic radiation

First Posted Date: 2009-04-23

Last Posted Date: 2011-02-24

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 63

Registration Number: NCT00886678

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Paclitaxel-Loaded Polymeric Micelle and Carboplatin as First-Line Therapy in Treating Patients With Advanced Ovarian Cancer

Phase 1

Conditions: Ovarian Cancer

First Posted Date: 2009-04-23

Last Posted Date: 2013-08-02

Lead Sponsor: Asan Medical Center

Target Recruit Count: 74

Registration Number: NCT00886717

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Yonsei Cancer Center at Yonsei University Medical Center, Seoul, Korea, Republic of
🇰🇷
Asan Medical Center - University of Ulsan College of Medicine, Seoul, Korea, Republic of

and more 1 locations

Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Phase 2

Completed

Conditions: Liver Cancer

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Sorafenib

First Posted Date: 2009-04-03

Last Posted Date: 2017-02-07

Lead Sponsor: University of Miami

Target Recruit Count: 11

Registration Number: NCT00875615

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: NSCLC

Interventions: Biological: Imprime PGG Injection
Biological: Cetuximab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-04-03

Last Posted Date: 2016-11-29

Lead Sponsor: HiberCell, Inc.

Target Recruit Count: 90

Registration Number: NCT00874848

Locations: 🇺🇸
Allison Cancer Center, Midland, Texas, United States
🇩🇪
Municipal Clinic Frankfurt Hoescht, Frankfurt, Germany
🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States

and more 11 locations

Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Imprime PGG® Injection
Biological: Bevacizumab
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2009-04-02

Last Posted Date: 2017-03-03

Lead Sponsor: HiberCell, Inc.

Target Recruit Count: 90

Registration Number: NCT00874107

Locations: 🇺🇸
Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
University of Texas Health Science Center, San Antonio, San Antonio, Texas, United States

and more 7 locations

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Biological: Cetuximab
Biological: IMC-A12 (cixutumumab)
Drug: Carboplatin

First Posted Date: 2009-03-27

Last Posted Date: 2018-06-01

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 64

Registration Number: NCT00870870

Locations: 🇺🇸
ImClone Investigational Site, Cincinnati, Ohio, United States

Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System

Phase 1

Completed

Conditions: Medulloblastoma
Pineoblastoma
Supratentorial Embryonal Tumor, Not Otherwise Specified

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Etoposide Phosphate
Drug: Isotretinoin
Other: Laboratory Biomarker Analysis
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Thiotepa
Drug: Vincristine Sulfate
Drug: Vorinostat

First Posted Date: 2009-03-23

Last Posted Date: 2022-01-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 33

Registration Number: NCT00867178

Locations: 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Lurie Children's Hospital-Chicago, Chicago, Illinois, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy